Transgene SA (TNG) - Total Assets
Based on the latest financial reports, Transgene SA (TNG) holds total assets worth €40.99 Million EUR (≈ $47.92 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Transgene SA book value and equity for net asset value and shareholders' equity analysis.
Transgene SA - Total Assets Trend (1997–2024)
This chart illustrates how Transgene SA's total assets have evolved over time, based on quarterly financial data.
Transgene SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Transgene SA's total assets of €40.99 Million consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 39.5% |
| Accounts Receivable | €1.19 Million | 2.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €62.00K | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (1997–2024)
This chart illustrates how Transgene SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TNG market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transgene SA's current assets represent 49.0% of total assets in 2024, a decrease from 58.5% in 1997.
- Cash Position: Cash and equivalents constituted 39.5% of total assets in 2024, down from 47.3% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 2.8% of total assets.
Transgene SA Competitors by Total Assets
Key competitors of Transgene SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Transgene SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.54 | 1.57 | 2.43 |
| Quick Ratio | 0.54 | 1.57 | 1.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-18.45 Million | €6.95 Million | €33.80 Million |
Transgene SA - Advanced Valuation Insights
This section examines the relationship between Transgene SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.86 |
| Latest Market Cap to Assets Ratio | 5.48 |
| Asset Growth Rate (YoY) | -6.7% |
| Total Assets | €42.17 Million |
| Market Capitalization | $231.18 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Transgene SA's assets at a significant premium (5.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Transgene SA's assets decreased by 6.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Transgene SA (1997–2024)
The table below shows the annual total assets of Transgene SA from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €42.17 Million ≈ $49.31 Million |
-6.73% |
| 2023-12-31 | €45.22 Million ≈ $52.86 Million |
-31.94% |
| 2022-12-31 | €66.44 Million ≈ $77.67 Million |
-34.76% |
| 2021-12-31 | €101.84 Million ≈ $119.06 Million |
+19.17% |
| 2020-12-31 | €85.45 Million ≈ $99.90 Million |
-26.00% |
| 2019-12-31 | €115.48 Million ≈ $135.00 Million |
+6.39% |
| 2018-12-31 | €108.54 Million ≈ $126.90 Million |
+7.60% |
| 2017-12-31 | €100.87 Million ≈ $117.93 Million |
-17.96% |
| 2016-12-31 | €122.95 Million ≈ $143.74 Million |
+21.89% |
| 2015-12-31 | €100.87 Million ≈ $117.93 Million |
-28.44% |
| 2014-12-31 | €140.95 Million ≈ $164.79 Million |
+12.00% |
| 2013-12-31 | €125.85 Million ≈ $147.13 Million |
-21.57% |
| 2012-12-31 | €160.46 Million ≈ $187.60 Million |
-17.11% |
| 2011-12-31 | €193.58 Million ≈ $226.32 Million |
-13.46% |
| 2010-12-31 | €223.69 Million ≈ $261.51 Million |
+126.72% |
| 2009-12-31 | €98.66 Million ≈ $115.35 Million |
-22.10% |
| 2008-12-31 | €126.65 Million ≈ $148.06 Million |
-1.30% |
| 2007-12-31 | €128.31 Million ≈ $150.01 Million |
+293.54% |
| 2006-12-31 | €32.60 Million ≈ $38.12 Million |
+27.85% |
| 2004-12-31 | €25.50 Million ≈ $29.81 Million |
-44.34% |
| 2003-12-31 | €45.82 Million ≈ $53.57 Million |
-31.49% |
| 2002-12-31 | €66.88 Million ≈ $78.19 Million |
-22.61% |
| 2001-12-31 | €86.42 Million ≈ $101.03 Million |
+80.27% |
| 2000-12-31 | €47.94 Million ≈ $56.04 Million |
-28.33% |
| 1999-12-31 | €66.89 Million ≈ $78.20 Million |
-21.14% |
| 1998-12-31 | €84.82 Million ≈ $99.16 Million |
+181.28% |
| 1997-12-31 | €30.15 Million ≈ $35.25 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more